Data show that dose-response relationships and long-term safety of ICS in people with chronic obstructive pulmonary disease are unclear and require further investigation.
Lauren Stonerock, PharmD
Advertisement
Articles by Lauren Stonerock, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Report Details Rising Incidence of Invasive Lobular Carcinoma
2
Mind the Gap: Pharmacy’s Future as AI Evolves in Health Care
3
Breaking News: AstraZeneca, White House Announce Most-Favored-Nation Deal
4
The 3 Skills You Will Need Most
5
